SCHEMBL20140433

SCHEMBL20140433

Ic1nn(Cc2cncnc2)c2ncccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.49
CYP1B1 Q16678 4/20 0.35
MET P08581 1/20 0.35
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TP53 P04637 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
GABRA5 P31644 1/20 0.34
ALDH1A1 P00352 2/20 0.33
PKM P14618 2/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
CHRM1 P11229 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20161099 0.83 L3MBTL1 (0.72) L3MBTL1LMNAMAPK1HTTSMN1; SMN2
SCHEMBL20140277 0.80 ELANE (0.46) L3MBTL1LMNAMAPK1HTTSMN1; SMN2
SCHEMBL4666470 0.77 MAPT (0.54) L3MBTL1LMNAPTGDR2ALDH1A1MAPT
SCHEMBL14488354 0.76 GRIN1 (0.37)
SCHEMBL27898869 0.75 L3MBTL1 (0.42) L3MBTL1TP53ALDH1A1MAPTKDM4E
SCHEMBL10063596 0.75 L3MBTL1 (0.46) L3MBTL1MAPK1TP53ALDH1A1MAPT
SCHEMBL23161931 0.73 CYP1B1 (0.40) CYP1B1GABRA5KDM4E
SCHEMBL174998 0.73 MAPT (0.53) L3MBTL1MAPT
SCHEMBL21787380 0.72 L3MBTL1 (0.44) L3MBTL1PTGDR2
SCHEMBL1639832 0.72 ALOX15 (0.43) L3MBTL1PTGDR2MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
EP-3538520-A2 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2019-09-18 EP disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071318-A1 SGC STIMULATORS GUCY1A2, GMPS, PDE2A L3MBTL1 4698/4885CYP1B1 1988/4885MET 2948/4885
US-20220017515-A1 sGC STIMULATORS GUCY1A2, PRKG1, PDE2A L3MBTL1 4695/4885CYP1B1 2011/4885MET 2761/4885
US-12435080-B2 sGC stimulators GUCY1A2, PRKG1, PDE2A L3MBTL1 4695/4885CYP1B1 2011/4885MET 2761/4885
US-11180493-B2 SGC stimulators GUCY1A2, GMPS, PDE2A L3MBTL1 4698/4885CYP1B1 1988/4885MET 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.